Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Novartis Ag

Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals, Inc.

Tisento Therapeutics Inc.

Irm LLC

Paul A Renhowe

Cynthia Shafer

Christopher McBride

Savithri Ramurthy

Sabina Pecchi

Sharadha Subramanian

Glen Robert Rennie

Rajesh R Iyengar

Daniel J Poon

Takashi Nakai

Timothy D Machajewski

Thomas Wai-Ho Lee

Joon Jung

Ara Mermerian

G-Yoon Jamie Im

Timothy Claude Barden

Paul Andrew Barsanti

David Duhl

Barry Haskell Levine

Karthik Iyer

James Edward Sheppeck

Nicholas Robert Perl

Annette Olga Walter

Elisa Jazan

Mark G Currie

Joel D Moore

Kris Mendenhall

Payman Amiri

William R McCrea

Xiang Y Yu

Tinya Abrams

Lei Jia

Colleen Hudson

Kimberly Kafadar Long

George Todd Milne

Rustum S Boyce

Nathan Brammeier

Teresa Hansen

John M Nuss

Weibo Wang

Clarke Bentley Taylor

Yi Xia

Wendy Fantl

Ryan N Constantine

Leonard Sung

Teresa E Pick

James Jia

Kelly Wayman

Megan C Phillips

Kim Tang

Hong Yang

Martin Sendzik

Kirk William Johnson

Mark Knapp

Keith Bruce Pfister

Qiong Zhang

Allan S Wagman

Stephen David Harrison

Kenneth Walter Bair

Eric J Martin

Rama Jain

Abran Q Costales

Darrin Stuart

Liana Marie Lagniton

Elizabeth J Mieuli

Anu Sharma

Rustum Boyce

Kay Huh

Vincent P Le

Daniel T Chu

Dane A Goff

David B Ring

Aaron Matthew Smith

Zhi-Jie Ni

Lynn Seely

Jeff Xianming Jin

Rajinder Paul Singh

Pingda Ren

Pamela Ann Albaugh

Chengzhi Zhang

Shifeng Pan

Shenlin Huang

David C Myles

Xing Wang

Qiang Ding

Guobao Zhang

Yongping Xie

Angelika Fretzen

Yasheen Zhou

Xiaodong Lin

Simon C Ng

Zuosheng Liu

Gregory B Chopiuk

Xia Wang

Alice C Rico

Daniel P Zimmer

Marion Wiesmann

Carla C Heise

Charles Kim

Zilin Huang

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:

SGC stimulators

The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of Nonalcoholic Steatohepatitis (NASH).

Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein J, n, R, R, R, R, R, m and X as defined herein. 

Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, J, n, J, J, o, R, R, W, J, r, J, s, Z, Zand Zare as defined herein.

Growing community of inventors

Danville, CA, United States of America

Paul A Renhowe